Pharmac agrees to fund drug for those with spinal muscular atrophy after years of lobbying
+News
Pharmac agrees to fund drug for those with spinal muscular atrophy after years of lobbying
RNZ
Wednesday 28 September 2022, 11:25 AM
Nusinersen (branded as Spinraza) would be the first medicine publicly funded for people who have spinal muscular atrophy [Image Jon Tyson via Unsplash]
New medicines for those with a rare spinal disease and people at risk of anaphylaxis are set to be publicly funded.
Pharmac is looking at funding a
Chemist Warehouse is sponsoring the Young Pharmacist of the Year Award in the 2025 New Zealand Primary Healthcare Awards | He Tohu Mauri Ora. The Chemist Warehouse leadership team explains what it means to be a Stellar Supporter